Indication and Limitation of Use

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test for this use: as first-line therapy in combination… read more

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13)… read more

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test… read more

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test for this use: as first-line therapy in combination with FOLFOX, as monotherapy following disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy.

Vectibix® is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.

×
×

You are now leaving Vectibix.com

Please know that the sponsors of this site are not responsible for content on the site you are about to enter.

Cancel
Continue

Vectibix® co-pay assistance is available for your patients

Commercial insurance

  • The Vectibix FIRST STEPTM Program can help reduce out-of-pocket costs for your Vectibix® patients who have commercial insurance*
  • Visit AmgenFirststep.com for more information about eligibility needs and coverage limits

Medicare or Medicaid

  • If your patient is covered by Medicare or Medicaid and needs help with out-of-pocket costs, he or she may be eligible for support from an Independent Co‑pay Foundation
  • Visit AmgenAssistOnline.com or call 1‑888‑4ASSIST (1‑888‑427‑7478) for referral to an Independent Co-pay Foundation

Uninsured or underinsured

  • If your patient is uninsured or underinsured, he or she may be eligible to get help for their Vectibix® prescription from The Safety Net Foundation
  • Call 1‑888‑SN‑AMGEN (1‑888‑762‑6436) to find out about your patients' eligibility

*Patient Eligibility Requirements: Patient must be prescribed Vectibix® treatment. Must have private commercial health insurance that covers medication costs for Vectibix®. Not a participant in any federal-, state-, or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), the Department of Defense (DoD), or TriCare. Patients may not seek reimbursement for value received from the Vectibix® FIRST STEP Program from any third-party payers, including flexible spending accounts or healthcare savings accounts. If at any time patients begin receiving coverage under any federal-, state-, or government-funded healthcare program, patients will no longer be eligible to participate in the Vectibix® FIRST STEP Program and must call 1-888-65-STEP1 (1-888-657-8371) Monday through Friday, 9 AM-8 PM EST, to stop participation. Restrictions may apply. Amgen reserves the right to revise or terminate this program, in whole or in part, without notice at any time. This is not health insurance. Program invalid where otherwise prohibited by law. Register before any Vectibix® treatment.

Coverage limits: Program covers out-of-pocket medication costs for Vectibix® only. Program does not cover any other costs related to office visit or administration of Vectibix®. Other restrictions may apply. No out-of-pocket for first dose or cycle; $25 out-of-pocket cost for subsequent dose or cycle; for Vectibix® maximum benefit of $5,000 per patient per 6-month calendar period. Patient is responsible for costs above these amounts.

Amgen provides donation to various nonprofit independent entities but has no influence over the distribution of the funds.

Site Map
×